Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Despite the impressive response rate to third-generation EGFR-TKIs, resistance inevitably develops in most patients. Stereotactic radiotherapy plays a growing role in the management of patients with brain metastasis. This study aims to evaluate the efficacy and safety of stereotactic radiotherapy for oligo-residual intracranial disease after first-line third-generation EGFR Inhibitors.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 3rd generation EGFR-TKI+SRS | Experimental | The experimental arm will undergo stereotactic radiotherapy targeting all residual lesions in the brain (completed in a single or multiple treatment courses within one month), while continuing EGFR-TKI therapy until disease progression or intolerable toxicity occurs. |
|
| 3rd generation EGFR-TKI | Active Comparator | The control group will receive 3rd generation EGFR-TKI until disease progression or intolerable toxicity occurs. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EGFR-TK Inhibitor | Drug | Patients will receive EGFR-TKI until confirmed progression or unacceptable toxicity. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Progression-free survival | PFS was measured from the date of randomization to the date of disease progression as defined by Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 or death | Two years |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival | OS was defined as the time from the date of randomization until death by any cause. Participants still alive at the time of data analysis were censored at the date of last follow-up. | Three years |
| Intracranial progression-free survival |
Not provided
Inclusion Criteria:
Pathologically confirmed non-small cell lung cancer;
Clinical stage IV (AJCC, 8th edition, 2017);
EGFR mutations: EGFR L858R, EGFR exon 19 deletion;
Age ≥18 years;
KPS score ≥70;
Brain metastasis at the time of diagnosis;
Complete baseline imaging assessment of metastatic lesions, including enhanced MRI for brain;
Receiving first-line treatment with third-generation EGFR inhibitors;
After 3-6 months of third-generation EGFR inhibitor treatment, imaging review indicates no progression of extracranial lesions, and brain lesions are evaluated by thin-layer (1mm layer) enhanced MRI, meeting the following criteria:
No more than 10 remaining brain lesions;
The maximum diameter of the remaining brain lesions does not exceed 3cm;
At least one remaining brain lesion has a diameter greater than 5mm;
Patient informed consent.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Zhengfei Zhu, MD | Fudan University | Principal Investigator |
| Xuwei Cai | Shanghai Chest Hospital | Principal Investigator |
| Qian Chu | Tongji Hospital | Principal Investigator |
| Xiaorong Dong | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Principal Investigator |
| Lin Wu | Hunan Cancer Hospital | Principal Investigator |
| Rongrong Zhou | Xiangya Hospital of Central South University | Principal Investigator |
| Guang Han | Hubei Cancer Hospital | Principal Investigator |
| Hui Zhu | Shandong Cancer Hospital and Institute | Principal Investigator |
| Jinjun Ye | Jiangsu Cancer Institute & Hospital | Principal Investigator |
| Xiaojia Cui |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | Shanghai Municipality | 200030 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001932 | Brain Neoplasms |
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D016634 | Radiosurgery |
| ID | Term |
|---|---|
| D011878 | Radiotherapy |
| D013812 | Therapeutics |
| D013238 | Stereotaxic Techniques |
| D019635 | Neurosurgical Procedures |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Stereotactic radiotherapy | Radiation | Patients with oligo-residual intracranial disease after treatment with EGFR-TKI will be treated with SRS of all intracranial lesions. The choice of dose-fractionation regimen is at the discretion of the treating radiation oncologist. |
|
iPFS was defined as the time from the start of randomization to the occurrence of intracranial disease progression or death. If the subject first experiences extracranial disease progression (without concurrent intracranial disease progression), the date of first extracranial disease progression will be used as the cut-off date. For patients who have not progressed at the time of analysis, the date of their last contact will be used as the cut-off date. |
| Two years |
| Health-related quality of life per QLQ-C30 | Health-related quality of life was evaluated using the QLQ-C30 questionnaires to assess health-related quality of life. | Two years |
| Health-related quality of life per QLQ-LC13 | Health-related quality of life was evaluated using the QLQ-LC13 questionnaires to assess health-related quality of life. | Two years |
| Percentage of Participants With Adverse Events | Treatment-related adverse events were assessed and graded according to CTCAE v. 5.0. | Two years |
| The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China |
| Principal Investigator |
| Guomei Tai | The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China | Principal Investigator |
| Zhiyong Yuan | Tianjin Medical University Cancer Institute and Hospital | Principal Investigator |
| Dejun XIng | Jilin Provincial Tumor Hospital | Principal Investigator |
| Jichen Ren | Jilin Provincial Tumor Hospital | Principal Investigator |
| Jiancheng Li | Fujian Cancer Hospital | Principal Investigator |
| Yanyang Wang | General Hospital of Ningxia Medical University | Principal Investigator |
| Chuangzhou Rao | Ningbo No.2 Hospital | Principal Investigator |
| Bing Lu | The Affiliated Hospital Of Guizhou Medical University | Principal Investigator |
| Zhongyi Dong | Nanfang Hospital, Southern Medical University | Principal Investigator |
| Jiwei Liu | The First Affiliated Hospital of Dalian Medical University | Principal Investigator |
| Zhenzhou Yang | The Second Affiliated Hospital of Chongqing Medical University | Principal Investigator |
| Hongqing Zhuang | Peking University Third Hospital | Principal Investigator |
| Anwen Liu | Nanchang University Second Affiliated Hospital | Principal Investigator |
| Haihua Yang | Taizhou Hospital Affiliated to Wenzhou Medical University | Principal Investigator |
| Fang Liu | Chinese PLA General Hospital | Principal Investigator |
| Yong Mao | Affiliated Hospital of Jiangnan University | Principal Investigator |
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D013514 |
| Surgical Procedures, Operative |
| D008919 | Investigative Techniques |